Psilocybin Feasible for Treatment-Resistant Depression in NHS Setting

This NHS-based feasibility RCT provides one of the first placebo-controlled signals that a single 25-mg psilocybin dose with psychological support can produce large short-term reductions in depressive symptoms in treatment-resistant depression, while underscoring the unresolved problem of functional unblinding.

psilocybinCOMP360serotonergic psychedelicstreatment-resistant depressionmajor depressive disorderfeasibility RCTpsychopharmacologyNHSMADRSpsychedelic-assisted therapy Psychiatry / Psychopharmacology

Background Information

Psilocybin shows promise for treatment-resistant major depression.

This study explores psilocybin as a potential treatment for patients with treatment-resistant major depressive disorder, which is a difficult-to-treat condition. The study found a significant improvement in depression scores with psilocybin compared to placebo, with a difference of -10.41 on the MADRS at week 3. These results suggest psilocybin could be beneficial for some patients with treatment-resistant depression, but a confirmatory trial is needed. The study was limited by its small size and feasibility-focused design. Psilocybin shows promise for treatment-resistant depression, warranting further investigation.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Rucker JJ, Mantingh T, Kerr-Gaffney J, Bird C, Chu P, Modlin NL, Campbell-Coker K, Hambleton S, Seath P, Hignett R, Fennema D, Hampsey E, Tsapekos D, Thomas RJ, Cattell J, Jafari H, Day C, Borissova A, Lloyd M, Boardman-Pretty T, Seynaeve M, Askari F, Creed M, Baxter L, Rifkin-Zybutz R, Butler M, Jelen LA, Carter B, Young AH

Citation: Rucker JJ, Mantingh T, Kerr-Gaffney J, et al. Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial. Nature medicine. 2026. doi:10.1038/s41591-026-04541-0

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →